(702) 683-8946

Monday - Friday 9am to 5pm

triangle
ad1

http://crweworld.com/assets/images/ad/crwe_tech.jpg

Your Technology Source, Your Technology Team

Server Maintenance, Web Development, Mobile Application Solutions, SEO Services and more

Contact Us: contact@crwetech.com

www.CRWETech.com

ad2

http://crweworld.com/assets/images/ad/ad4.png

Place Your Ad Here! Advertise your business online on CRWE WORLD. Your Company, product, or service in front of the world!

Contact Us: contact@crweworld.com

www.CRWEWorld.com

ad3

http://crweworld.com/assets/img/crwe_info.png

CRWE Info ( CRWE.Info ) provides news and updates about Crown Equity Holdings Inc. and the CRWE World platform

www.crwe.info

ad4

http://crweworld.com/assets/images/ad/submit_a_press_release.jpg

Submit Your Press Release/News to the CRWE WORLD Network for $14.95! Increase Visibility, Boost Your Business

www.CRWEPressRelease.com

ad5

http://crweworld.com/assets/images/ad/Pathology_Laboratories.png

Quest Diagnostics Inc. (NYSE:DGX) offers the most extensive clinical testing network in the U.S. The Company's extensive test menu includes routine biological testing; complex and specialized molecular and gene-based testing, and anatomic pathology testing. These services primarily help identify disease or risk factors for disease and predict and monitor response to treatment.

www.QuestDiagnostics.com






897 Result: Intel

Nivalis Therapeutics and Alpine Immune Sciences Agree to Combine

April 18th, 2017

- Plan to Accelerate Development of Novel Immunotherapies Focused on Inflammation and Immuno-Oncology - - Combined Company Well Capitalized with $90 Million in Funding to Advance Discovery and Development - - Existing Investors OrbiMed Advisors. Read more

FBI Renews Contract with Inpixon Federal

April 18th, 2017

PALO ALTO, Calif. / CRWE PRESS RELEASE / April 18, 2017 – Inpixon (NASDAQ: INPX), a leading indoor positioning and data analytics company, today announced that subsidiary, Inpixon Federal, has been awarded a second option year re. Read more

Puma Biotechnology Announces FDA Advisory Committee to Review Neratinib for the Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer

April 17th, 2017

LOS ANGELES, Calif. / CRWE PRESS RELEASE / April 17, 2017 - Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has scheduled the New Drug Application (NDA) for n. Read more

AVEO Announces Submission of Response to Tivozanib Marketing Authorization Application Day 180 List of Outstanding Issues

April 13th, 2017

CAMBRIDGE, Mass. / CRWE PRESS RELEASE / April 13, 2017 - AVEO Oncology (NASDAQ: AVEO) today announced that its European licensee for tivozanib, EUSA Pharma, has submitted responses to the European Medicines Agency (EMA) Day 180 List of Outstanding Is. Read more

Arbitration Panel Awards Refund to BlackBerry

April 12th, 2017

SAN DIEGO / CRWE PRESS RELEASE / April 12, 2017 - Qualcomm Incorporated (NASDAQ: QCOM) announced a binding interim arbitration award requiring Qualcomm to refund a sum of $814.9 million, plus interest and attorneys’ fees, to BlackBerry Incorpor. Read more

Qualcomm Files Answer and Counterclaims to Apple Lawsuit

April 11th, 2017

– Highlights Apple’s efforts to devalue the fundamental Qualcomm technologies empowering the iPhone -- SAN DIEGO / CRWE PRESS RELEASE / April 10, 2017 - Qualcomm Incorporated (NASDAQ: QCOM) today filed its Answer and Counterclaims to t. Read more

Puma Biotechnology Presents Interim Results of Phase Ib/II FB-10 Trial of PB272 in Combination with Trastuzumab Emtansine (T-DM1) in HER2-Positive Metastatic Breast Cancer at the 2017 AACR Annual Meeting

April 02nd, 2017

LOS ANGELES, Calif. / CRWE PRESS RELEASE / April 2, 2017 - Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, announced that interim results from the Phase Ib/II FB-10 clinical trial of Puma’s investigational drug PB272 (nera. Read more

Puma Biotechnology Presents Results from the Phase II SUMMIT Trial of PB272 for ERBB2 (HER2) Mutant, HER2 Non-Amplified, Metastatic Cancer at the 2017 AACR Annual Meeting

April 02nd, 2017

LOS ANGELES, Calif. / CRWE PRESS RELEASE / April 2, 2017 - Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, announced that results from an ongoing Phase II clinical trial of Puma's investigational drug PB272 (neratinib) were . Read more

Puma Biotechnology Launches Expanded Access Program for PB272 (Neratinib) for U.S. Patients with HER2-Positive Breast Cancer or HER2-Mutated Cancer

April 02nd, 2017

Caligor Opco LLC to Provide Regulatory and Logistical Management LOS ANGELES, Calif. / CRWE PRESS RELEASE / April 2, 2017 - Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, has initiated an expanded access program (EAP) in the. Read more

Corindus Announces First Robotic-Assisted PCI Procedures Performed in Asia Using CorPath(R) GRX System

March 31st, 2017

Live Case Transmitted from Fu Wai Hospital to China Interventional Therapeutics Conference in Beijing Waltham, MA / CRWE PRESS RELEASE / March 31, 2017 - Corindus Vascular Robotics, Inc. (NYSE MKT: CVRS), a leading developer of precision vascular . Read more

Intel to Acquire Mobileye

March 13th, 2017

Combining Technology and Talent to Accelerate the Future of Autonomous Driving NEWS HIGHLIGHTS * Brings together Mobileye’s leading computer vision expertise with Intel’s high-performance computing and connectivity expertise to crea. Read more

Bombardier Wins Contract to Provide 70 FLEXITY Trams to Zurich

March 03rd, 2017

* Contract includes an option for 70 additional vehicles * Modern FLEXITY trams feature 20% more passenger capacity than vehicles currently in use in Zurich Berlin, Germany / CRWE PRESS RELEASE / March 1, 2017 - Rail technology leader Bombardier . Read more

Sierra Wireless selected by PrecisionHawk to enable drone safety and traffic management

February 23rd, 2017

Sierra Wireless and PrecisionHawk will demonstrate the LTE-enabled LATAS Platform at Mobile World Congress 2017 Vancouver, B.C. / CRWE PRESS RELEASE / February 23, 2017 - Sierra Wireless (NASDAQ: SWIR) (TSX: SW), a leading provider of fully integr. Read more

Pluristem Reports Second Quarter Fiscal 2017 Highlights & Provides Calendar 2017 Outlook

February 13th, 2017

HAIFA, Israel / CRWE PRESS RELEASE / February 13, 2017 - Pluristem Therapeutics Inc. (Nasdaq: PSTI, TASE: PSTI), a leading developer of placenta-based cell therapy products, today reported financial update and corporate and clinical developments for . Read more

Volkswagen prefers Sierra Wireless to enable next-generation connected vehicles with 4G LTE embedded modules

February 09th, 2017

Sierra Wireless AirPrime® AR Series embedded modules and Legato® platform will enable Car-Net connectivity for Volkswagen automobiles beginning in 2018 Vancouver, B.C. / CRWE PRESS RELEASE / February 09, 2017 - Sierra Wireless (NASDAQ: SWI. Read more

Load More Content